Literature DB >> 17275893

Repeated cannabinoid administration increases indices of noradrenergic activity in rats.

M E Page1, V C Oropeza, S E Sparks, Y Qian, A S Menko, E J Van Bockstaele.   

Abstract

The present study examined the impact of repeated administration of a synthetic cannabinoid agonist, WIN 55,212-2 on the coeruleo-cortical pathway, a circuit implicated in anxiety. Male Sprague-Dawley rats received repeated systemic injections of WIN 55,212-2 (3.0 mg/kg). A separate group of rats received repeated WIN 55,212-2 injections followed by a period of abstinence. Control animals received vehicle injections. Ninety minutes following the last injection on day 8, anxiety-related behavior was assessed using the elevated plus maze. The abstinent group was tested after another 8 days. Following behavioral testing, brain tissue was extracted from the locus coeruleus (LC) and probed for tyrosine hydroxylase (TH) expression. In a separate group of animals, in vivo microdialysis was used to monitor extracellular norepinephrine efflux in the frontal cortex following repeated WIN 55,212-2 administration and following a period of abstinence. Repeated administration of WIN 55,212-2 evoked an anxiogenic-like response that was accompanied by an increase in TH protein expression in the LC. A similar neurochemical profile was observed using in vivo microdialysis where an augmented increase in cortical norepinephrine efflux was identified in response to a systemic injection of WIN 55,212-2 on day 8. Anxiety-like behavior, catecholamine synthesizing enzyme levels and NE efflux returned to control values after 8 days of abstinence. The present findings indicate that repeated administration of a synthetic cannabinoid receptor agonist induces transient anxiety-like behaviors that correlate with increases in catecholamine synthesizing enzyme expression in the LC and augmented norepinephrine efflux in response to a challenge injection of WIN 55,212-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275893      PMCID: PMC1941574          DOI: 10.1016/j.pbb.2006.12.020

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  47 in total

Review 1.  Role of locus coeruleus in attention and behavioral flexibility.

Authors:  G Aston-Jones; J Rajkowski; J Cohen
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

2.  A.E. Bennett Research Award. Anatomic basis for differential regulation of the rostrolateral peri-locus coeruleus region by limbic afferents.

Authors:  E J Van Bockstaele; J Peoples; R J Valentino
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

Review 3.  Cellular and synaptic adaptations mediating opioid dependence.

Authors:  J T Williams; M J Christie; O Manzoni
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

4.  Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme.

Authors:  M Hernández; F Berrendero; I Suárez; L García-Gil; M Cebeira; K Mackie; J A Ramos; J Fernández-Ruiz
Journal:  Brain Res       Date:  2000-02-28       Impact factor: 3.252

5.  Effects of acute restraint stress on tyrosine hydroxylase mRNA expression in locus coeruleus of Wistar and Wistar-Kyoto rats.

Authors:  S A Sands; R Strong; J Corbitt; D A Morilak
Journal:  Brain Res Mol Brain Res       Date:  2000-01-10

Review 6.  Measuring normal and pathological anxiety-like behaviour in mice: a review.

Authors:  C Belzung; G Griebel
Journal:  Behav Brain Res       Date:  2001-11-01       Impact factor: 3.332

7.  Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex.

Authors:  V C Oropeza; M E Page; E J Van Bockstaele
Journal:  Brain Res       Date:  2005-06-07       Impact factor: 3.252

Review 8.  Use of the elevated plus maze in the search for novel anxiolytic agents.

Authors:  G R Dawson; M D Tricklebank
Journal:  Trends Pharmacol Sci       Date:  1995-02       Impact factor: 14.819

9.  The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being.

Authors:  L Degenhardt; W Hall; M Lynskey
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2001-05       Impact factor: 4.328

10.  Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.

Authors:  M D Aceto; S M Scates; B B Martin
Journal:  Eur J Pharmacol       Date:  2001-03-23       Impact factor: 4.432

View more
  31 in total

Review 1.  Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.

Authors:  Ana Franky Carvalho; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-24       Impact factor: 5.067

Review 2.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

3.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

4.  Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats.

Authors:  A F Carvalho; B A S Reyes; F Ramalhosa; N Sousa; E J Van Bockstaele
Journal:  Brain Struct Funct       Date:  2014-10-28       Impact factor: 3.270

Review 5.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

6.  Cannabinoids and novelty investigation: influence of age and duration of exposure.

Authors:  Krysta M Fox; Robert C Sterling; Elisabeth J Van Bockstaele
Journal:  Behav Brain Res       Date:  2008-10-05       Impact factor: 3.332

7.  Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors.

Authors:  Jillian L Scavone; Ken Mackie; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2009-11-18       Impact factor: 3.252

8.  Cannabinoid modulation of limbic forebrain noradrenergic circuitry.

Authors:  Ana F Carvalho; Kenneth Mackie; Elisabeth J Van Bockstaele
Journal:  Eur J Neurosci       Date:  2010-01-13       Impact factor: 3.386

9.  Stress system changes associated with marijuana dependence may increase craving for alcohol and cocaine.

Authors:  Helen C Fox; Keri L Tuit; Rajita Sinha
Journal:  Hum Psychopharmacol       Date:  2012-12-28       Impact factor: 1.672

10.  Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-16       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.